BPC-157 vs Pentadecapeptide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Body Protection Compound-157, Pentadecapeptide BPC 157
A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
Also: BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
The full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
Detailed Comparison
| Attribute | BPC-157 | Pentadecapeptide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | BPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis. | Like BPC-157, the pentadecapeptide modulates the nitric oxide system, promotes angiogenesis, and accelerates tissue healing. It interacts with multiple growth factor systems and has cytoprotective effects on various tissues. |
| Common Dosing | 250-500 mcg twice daily 1-2x daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection near injury site, or systemic | Subcutaneous injection |
| Typical Duration | 4-12 weeks in most research protocols | 4-12 weeks typical |
| Best Time to Take | Morning and evening (or near injury site timing) | Morning and evening (or near injury site timing) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract. 2025 AJSM systematic review: Of 544 articles screened, only 1 clinical study met inclusion criteria (rest were animal studies). Only 3 small human pilot studies exist (fewer than 30 total subjects). No pharmaceutical company has initiated FDA trials due to lack of patentability. FDA placed BPC-157 in Category 2 in September 2023. | Research largely overlaps with BPC-157 studies, showing tissue healing, gastroprotection, and recovery enhancement. The pentadecapeptide terminology is sometimes used interchangeably with BPC-157 in scientific literature. |
Frequently Asked Questions: BPC-157 vs Pentadecapeptide
What is the difference between BPC-157 and Pentadecapeptide?
BPC-157 is a healing peptide that a synthetic peptide derived from a protein found in human gastric juice. known for its remarkable tissue healing properties across multiple body systems. fda classified as category 2 in 2023, restricting compounding. Pentadecapeptide is a healing peptide that the full 15-amino acid sequence that includes bpc-157. while bpc-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice. The main differences lie in their mechanisms of action and clinical applications.
Which is better, BPC-157 or Pentadecapeptide?
Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while Pentadecapeptide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can BPC-157 and Pentadecapeptide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and Pentadecapeptide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.